Article Text

Download PDFPDF

British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
  1. Michael Huw Chapman1,2,
  2. Douglas Thorburn2,
  3. Gideon M Hirschfield3,
  4. George G J Webster1,
  5. Simon M Rushbrook4,
  6. Graeme Alexander2,
  7. Jane Collier5,
  8. Jessica K Dyson6,7,
  9. David EJ Jones7,
  10. Imran Patanwala8,9,
  11. Collette Thain10,
  12. Martine Walmsley11,
  13. Stephen P Pereira1,12
  1. 1 GI Division, UCL Hospitals NHS Foundation Trust, London, UK
  2. 2 Liver Unit, Royal Free London NHS Foundation Trust, London, UK
  3. 3 Toronto Centre for Liver Disease, University Health Network and University of Toronto, Toronto, Canada
  4. 4 Department of Hepatology, Norfolk and Norwich University Hospitals NHS Trust, Norwich, UK
  5. 5 Hepatology, John Radcliffe Hospital, Oxford, UK
  6. 6 Hepatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK
  7. 7 Institute of Cellular Medicine, Newcastle University, Newcastle, UK
  8. 8 Gastroenterology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK
  9. 9 University of Liverpool, Liverpool, UK
  10. 10 PBC Foundation, Edinburgh, UK
  11. 11 Chair of Trustees PSC Support, Didcot, UK
  12. 12 Institute for Liver & Digestive Health, University College London, London, UK
  1. Correspondence to Prof Stephen P Pereira; stephen.pereira{at}ucl.ac.uk

Abstract

These guidelines on the management of primary sclerosing cholangitis (PSC) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included medical representatives from hepatology and gastroenterology groups as well as patient representatives from PSC Support. The guidelines aim to support general physicians, gastroenterologists and surgeons in managing adults with PSC or those presenting with similar cholangiopathies which may mimic PSC, such as IgG4 sclerosing cholangitis. It also acts as a reference for patients with PSC to help them understand their own management. Quality of evidence is presented using the AGREE II format. Guidance is meant to be used as a reference rather than for rigid protocol-based care as we understand that management of patients often requires individual patient-centred considerations.

  • sclerosing cholangitis

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors The guidelines were conceived by SPP. MHC was the primary author of the draft documents and coordinated the amendments made after review of the writing committee. Additional regular review of the content was provided by SPP, DT, GGJW, GMH and MW. All authors contributed to authorship of the guidelines as members of the writing committee and agreed the content for publication. Final versions were submitted by MHC and SPP who take responsibility as guarantors for the overall content.

  • Funding SPP is supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre. GMH is supported by the National Institute for Health Research. No other funding was received for the production of these guidelines.

  • Competing interests DT – involvement in clinical trials in PSC (NGM, Takeda, Shire), funding from British Liver Trust, PSC Partners, PSC Support, EASL, SMR – Involvement in clinical trials in PSC and sits on the advisory board for FALK and Intercept. GH - medical adviser for PSC Support, speaker fees and educational support from Falk Pharma.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.